ZA200903495B - Substituted pyrimidines and their use as JNK Modulators - Google Patents
Substituted pyrimidines and their use as JNK ModulatorsInfo
- Publication number
- ZA200903495B ZA200903495B ZA200903495A ZA200903495A ZA200903495B ZA 200903495 B ZA200903495 B ZA 200903495B ZA 200903495 A ZA200903495 A ZA 200903495A ZA 200903495 A ZA200903495 A ZA 200903495A ZA 200903495 B ZA200903495 B ZA 200903495B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted pyrimidines
- jnk modulators
- jnk
- modulators
- pyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87362506P | 2006-12-08 | 2006-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200903495B true ZA200903495B (en) | 2010-04-28 |
Family
ID=39099641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200903495A ZA200903495B (en) | 2006-12-08 | 2009-05-20 | Substituted pyrimidines and their use as JNK Modulators |
Country Status (18)
Country | Link |
---|---|
US (1) | US8399462B2 (zh) |
EP (1) | EP2102194A1 (zh) |
JP (1) | JP5179509B2 (zh) |
KR (1) | KR101152162B1 (zh) |
CN (1) | CN101547917A (zh) |
AR (1) | AR064133A1 (zh) |
AU (1) | AU2007328981B2 (zh) |
BR (1) | BRPI0720003A2 (zh) |
CA (1) | CA2670375A1 (zh) |
CL (1) | CL2007003502A1 (zh) |
IL (1) | IL198543A0 (zh) |
MX (1) | MX2009005508A (zh) |
NO (1) | NO20091942L (zh) |
PE (1) | PE20081507A1 (zh) |
RU (1) | RU2493155C2 (zh) |
TW (1) | TW200831101A (zh) |
WO (1) | WO2008068171A1 (zh) |
ZA (1) | ZA200903495B (zh) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2690327A1 (en) * | 2007-06-15 | 2008-12-18 | Thomas P. Cleary | A novel process for the preparation of 3-amino-pentan-1,5-diol |
EP2426109B1 (en) * | 2007-10-23 | 2013-12-18 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
KR101368079B1 (ko) * | 2008-05-16 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Jnk 의 억제제 |
EP2379527A1 (en) | 2008-12-19 | 2011-10-26 | F. Hoffmann-La Roche AG | Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation |
CN102325771B (zh) * | 2009-02-24 | 2014-10-29 | 霍夫曼-拉罗奇有限公司 | 作为jnk调节剂的咪唑并[1,2-a]吡啶类 |
CN102480966B (zh) | 2009-06-12 | 2015-09-16 | 达娜-法勃肿瘤研究所公司 | 融合的杂环化合物及其用途 |
CN102471319B (zh) * | 2009-08-10 | 2014-06-18 | 霍夫曼-拉罗奇有限公司 | Jnk的抑制剂 |
CN102811619B (zh) * | 2009-11-13 | 2015-04-22 | 金纳斯克公司 | 激酶抑制剂 |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
KR20130091308A (ko) * | 2010-06-04 | 2013-08-16 | 에프. 호프만-라 로슈 아게 | Jnk 억제제 |
CN102918035B (zh) * | 2010-06-04 | 2015-05-27 | 霍夫曼-拉罗奇有限公司 | 用作jnk的抑制剂的2-氨基-嘧啶衍生物 |
WO2012106522A2 (en) | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
EP2684880B1 (en) | 2011-03-10 | 2018-02-28 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
CN113243374B (zh) | 2012-10-02 | 2022-04-26 | 拜耳农作物科学股份公司 | 作为杀虫剂的杂环化合物 |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
EP2964221B1 (en) | 2013-03-04 | 2017-12-06 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134776A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
WO2015073344A1 (en) * | 2013-11-14 | 2015-05-21 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
EP3489232A3 (en) | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10954240B2 (en) | 2014-09-03 | 2021-03-23 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
CN112457298B (zh) * | 2014-12-11 | 2024-05-07 | 贝达医药公司 | 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂 |
CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza |
WO2017133658A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
KR102195348B1 (ko) * | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
EP4155308A4 (en) * | 2020-07-14 | 2024-04-17 | Wuhan Ll Science And Tech Development Co Ltd | ROCK INHIBITOR, METHOD FOR PREPARING IT AND ITS USE |
CN113563310B (zh) * | 2021-06-25 | 2022-10-11 | 浙江工业大学 | 一种4-(1-甲基吲哚-3-基)嘧啶类衍生物及其应用 |
CN114790174B (zh) * | 2022-04-14 | 2023-09-29 | 淮阴工学院 | 一种连续合成1h-吲唑类化合物的方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4788195A (en) * | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
CZ20023199A3 (cs) * | 2000-02-25 | 2003-05-14 | F. Hoffmann-La Roche Ag | Modulátory receptoru adenosinu |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
US7078410B2 (en) * | 2001-02-20 | 2006-07-18 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders |
EA005974B1 (ru) * | 2001-02-23 | 2005-08-25 | Мерк Энд Ко., Инк. | N-замещенные неарильные гетероциклические антагонисты nmda/nr2b |
US20040171630A1 (en) * | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
JP2005524609A (ja) * | 2001-12-17 | 2005-08-18 | スミスクライン ビーチャム コーポレーション | ピラゾロピリダジン誘導体 |
TW200302722A (en) | 2002-02-13 | 2003-08-16 | Astrazeneca Ab | Therapeutic agents |
EP1554269A1 (en) | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
US7855205B2 (en) * | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
CA2608333A1 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
CA2662998C (en) | 2006-09-08 | 2015-10-06 | F. Hoffmann-La Roche Ag | Benzotriazole kinase modulators |
EP2057146A1 (en) | 2006-10-02 | 2009-05-13 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
MX2009003821A (es) | 2006-10-10 | 2009-05-25 | Amgen Inc | Compuestos de n-aril pirazol para usarse contra la diabetes. |
EP2379527A1 (en) * | 2008-12-19 | 2011-10-26 | F. Hoffmann-La Roche AG | Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation |
-
2007
- 2007-11-28 AU AU2007328981A patent/AU2007328981B2/en not_active Expired - Fee Related
- 2007-11-28 BR BRPI0720003A patent/BRPI0720003A2/pt not_active IP Right Cessation
- 2007-11-28 CA CA002670375A patent/CA2670375A1/en not_active Abandoned
- 2007-11-28 WO PCT/EP2007/062920 patent/WO2008068171A1/en active Application Filing
- 2007-11-28 KR KR1020097011056A patent/KR101152162B1/ko not_active IP Right Cessation
- 2007-11-28 EP EP07847445A patent/EP2102194A1/en not_active Withdrawn
- 2007-11-28 JP JP2009539701A patent/JP5179509B2/ja not_active Expired - Fee Related
- 2007-11-28 CN CNA2007800450228A patent/CN101547917A/zh active Pending
- 2007-11-28 MX MX2009005508A patent/MX2009005508A/es not_active Application Discontinuation
- 2007-11-28 RU RU2009125672/04A patent/RU2493155C2/ru not_active IP Right Cessation
- 2007-12-05 AR ARP070105424A patent/AR064133A1/es not_active Application Discontinuation
- 2007-12-05 CL CL200703502A patent/CL2007003502A1/es unknown
- 2007-12-06 TW TW096146549A patent/TW200831101A/zh unknown
- 2007-12-07 US US12/001,021 patent/US8399462B2/en not_active Expired - Fee Related
- 2007-12-07 PE PE2007001744A patent/PE20081507A1/es not_active Application Discontinuation
-
2009
- 2009-05-04 IL IL198543A patent/IL198543A0/en unknown
- 2009-05-19 NO NO20091942A patent/NO20091942L/no not_active Application Discontinuation
- 2009-05-20 ZA ZA200903495A patent/ZA200903495B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007328981A1 (en) | 2008-06-12 |
AU2007328981B2 (en) | 2013-07-11 |
KR101152162B1 (ko) | 2012-07-10 |
AR064133A1 (es) | 2009-03-11 |
WO2008068171A9 (en) | 2009-07-16 |
BRPI0720003A2 (pt) | 2018-09-18 |
US20080146565A1 (en) | 2008-06-19 |
PE20081507A1 (es) | 2008-11-12 |
CN101547917A (zh) | 2009-09-30 |
IL198543A0 (en) | 2010-02-17 |
TW200831101A (en) | 2008-08-01 |
RU2009125672A (ru) | 2011-01-20 |
CL2007003502A1 (es) | 2008-06-27 |
MX2009005508A (es) | 2009-06-03 |
EP2102194A1 (en) | 2009-09-23 |
KR20090075877A (ko) | 2009-07-09 |
NO20091942L (no) | 2009-07-07 |
JP5179509B2 (ja) | 2013-04-10 |
CA2670375A1 (en) | 2008-06-12 |
JP2010511655A (ja) | 2010-04-15 |
US8399462B2 (en) | 2013-03-19 |
WO2008068171A1 (en) | 2008-06-12 |
RU2493155C2 (ru) | 2013-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200903495B (en) | Substituted pyrimidines and their use as JNK Modulators | |
TWI561237B (en) | Substituted dihydropyrazolones and their use | |
GB0701426D0 (en) | Compounds and their use | |
IL194865A (en) | Amorophorins that are conserved in Heluaryl and their use | |
HK1208000A1 (zh) | 鋶化合物及其用途 | |
IL191139A0 (en) | Novel pyridopyrazines and their use as modulators of kinases | |
IL187686A0 (en) | Aminopyrimidines as kinase modulators | |
IL187693A0 (en) | Aminopyrimidines as kinase modulators | |
IL187692A0 (en) | Alkylquinoline and alkylquinazoline kinase modulators | |
GB0611115D0 (en) | Compounds and their use | |
ZA200810565B (en) | Pyrimidine derivatives and their use as pesticides | |
EP2170874A4 (en) | NEW COMPOUNDS AND THEIR USE | |
EP2133326A4 (en) | NEW PSEUDOGLYCOLIPID AND ITS USE | |
ZA200803864B (en) | Novel pyridopyrazines and their use as modulators of kinases | |
EP2067480A4 (en) | MUSCLIN RECEPTOR AND USE THEREOF | |
TWI366005B (en) | Optical plate and application thereof | |
GB0619611D0 (en) | Compounds and their use | |
ZA200800275B (en) | Aminopyrimidines as kinase modulators | |
ZA200800274B (en) | Aminopyrimidines as kinase modulators | |
ZA200800272B (en) | Alkylquinoline and alkylquinazoline kinase modulators | |
HU0600122D0 (en) | New compounds and their use | |
GB0619609D0 (en) | Compounds and their use | |
GB0610888D0 (en) | Compounds and their use | |
GB0603376D0 (en) | Compounds and their use | |
GB0603374D0 (en) | Compounds and their use |